Thalidomide for nausea in pancreatic cancer patients
Treatments studied
Part of Cancer, Digestive system, Hormones & metabolism clinical trials.
This trial tests whether adding thalidomide to standard chemotherapy can help reduce nausea and vomiting in people with advanced pancreatic cancer. It is for patients who have not yet received any cancer treatment.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 to 80 years old.
- You have been diagnosed with metastatic pancreatic adenocarcinoma (cancer that has spread).
- You have not had any prior cancer treatment for this disease.
- You are not pregnant or breastfeeding, and you agree to use birth control if needed.
- You do not have active inflammation of the digestive tract, like pancreatitis or gallbladder infection.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether giving extra diabetes medication along with standard chemotherapy can help control blood sugar and improve outcomes in people with pancreatic cancer that has spread. It may help you manage diabetes better during treatment.
This trial tests a new drug called IBI343 combined with standard chemotherapy for people with advanced pancreatic cancer that cannot be removed by surgery. The goal is to see if this combination can help shrink tumors or slow the cancer's growth.
This trial tests a combination of three drugs—gemcitabine, mitomycin C, and thalidomide—given in a low, frequent 'metronomic' schedule to treat advanced solid tumors that have already been treated. The goal is to see if this approach can slow or stop tumor growth with fewer side effects.
This study tests a new treatment for people with stage 4 pancreatic cancer who haven't yet had any treatment for advanced disease. The goal is to see if the new treatment can help shrink or control the cancer.
This trial tests a new combination of a migraine drug (rimegepant) with standard chemotherapy (AG) as a first treatment for advanced pancreatic cancer. It aims to see if this combo can help shrink tumors or slow the cancer.
This trial tests a new immunotherapy drug (ivonescimab) combined with targeted radiation and chemotherapy for people with pancreatic cancer. The goal is to see if this combination can shrink tumors and improve outcomes.
Hear when a new Pancreatic Cancer Stage IV trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.